Join us on Wednesday, July 15 for the live webinar
5:00 PM – 6:30 PM ET
1.5 AMA PRA Category 1 Credits^TM

Not an official event of ASCO20 Virtual. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

Supporters
This activity is supported by education grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, Lilly and Merck.

Contemporary Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Suresh S Ramalingam, MD

• Design, eligibility criteria and key efficacy and safety findings of the Phase III ADAURA trial evaluating adjuvant osimertinib versus placebo for early-stage NSCLC with an EGFR mutation after complete tumor resection
• Available efficacy and safety data with osimertinib as first-line therapy for patients with EGFR tumor mutations; documentation of an overall survival benefit with osimertinib as first-line therapy
• Biologic rationale for the design of clinical trials combining EGFR- and VEGFR-targeted therapy; key findings from the Phase III RELAY study leading to the FDA approval of erlotinib in combination with ramucirumab for patients with previously untreated metastatic NSCLC with EGFR mutations; ramifications for practice and future clinical trial design
• Impact of prior use of immune checkpoint inhibitors on the efficacy and tolerability of EGFR tyrosine kinase inhibitor therapy
• Optimal treatment of NSCLC that progresses on first-line osimertinib; spectrum of resistance mutations and role of rebiopsy

Optimal Therapeutic Approaches for Patients with ALK or ROS1 Rearrangements — Prof Solange Peters, MD, PhD

• Available clinical trial data informing the selection of first and later-line therapy for patients with metastatic NSCLC and an ALK rearrangement
• FDA approval of brigatinib for patients with NSCLC with an ALK rearrangement who have not previously received targeted therapy; appropriate integration into clinical practice
• Current and emerging treatment considerations for patients with NSCLC with ROS1 rearrangement; clinical trial data supporting the recent approval of entrectinib
• Intracranial response rates observed with entrectinib in patients with NSCLC with a ROS1 rearrangement and CNS involvement; implications for care

Research Advances Shaping the Current and Future Treatment of Lung Cancer with Other Targetable Abnormalities — Alexander E Drilon, MD

• Published data supporting the FDA approval of selpercatinib for patients with RET fusion-driven NSCLC
• Mechanism of action of, available data with and potential clinical role of pralsetinib for patients with NSCLC and RET fusions
• FDA approval and current clinical role of capmatinib for patients with NSCLC with MET exon 14 mutations
• Key efficacy and safety findings with and FDA breakthrough therapy designation for tepotinib for patients with MET exon 14 skipping mutations whose disease has progressed after platinum-based therapy
• Available clinical trial data informing the FDA approvals of larotrectinib and entrectinib for patients with solid tumors harboring NTRK gene fusions
• Published research with commercially available HER2-directed therapies for patients with NSCLC with HER2 overexpression or mutation
• Emerging safety and efficacy data with the novel KRAS G12C inhibitor AMG 510 for solid tumors with KRAS mutation

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives

• Evaluate available clinical trial findings supporting the use of osimertinib as first-line therapy for patients with non-small cell lung cancer (NSCLC) with EGFR mutations, and consider the effect of this information on current and future clinical practice.
• Recall the biologic rationale for and available data with the use of VEGF monoclonal antibodies in combination with EGFR tyrosine kinase inhibitors for patients with NSCLC with EGFR mutations, and discern the current clinical applicability of this treatment strategy.
• Appreciate recently presented Phase III trial findings supporting the efficacy of adjuvant osimertinib for patients with NSCLC with EGFR mutations after complete resection, and consider the potential effect of this information on current and future clinical practice.
• Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate patients with NSCLC in order to personalize therapeutic recommendations.
• Discuss the clinical relevance of a positive ROS1 mutation test result with appropriate patients with NSCLC, and optimally sequence available therapies for those with these genetic abnormalities.
• Assess available research evidence with approved and emerging RET inhibitors, and use this information to guide clinical care and protocol decisions for patients with newly diagnosed or progressive NSCLC harboring a RET fusion.
• Evaluate available clinical trial findings supporting the role of approved and investigational MET inhibitors, and identify patients with MET exon 14 skipping mutations who might benefit from treatment with these novel compounds.
• Recall the biologic rationale for and available data with the use of commercially available HER2-directed therapies for patients with NSCLC with HER2 overexpression or mutation, and discern the current and potential clinical applicability of this strategy.
• Recall the design of ongoing clinical trials evaluating other novel targeted strategies in patients with NSCLC and various genomic alterations, and counsel appropriate individuals about availability and participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Drilon — Advisory Committee and Consulting Agreements: AbbVie Inc, ArcherDX Inc, AstraZeneca Pharmaceuticals LP, Axis Pharmaceutics, Bayer HealthCare Pharmaceuticals, BeiGene, BerGenBio ASA, Blueprint Medicines, Elevation Oncology, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Hengrui Therapeutics Inc, Ignyta Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MORE Health Inc, Pfizer Inc, Remedica Ltd, Takeda Oncology, TP Therapeutics Inc, Tyra Biosciences, Verastem Inc, WebMD; Contracted Research: Exelixis Inc, Foundation Medicine, GlaxoSmithKline, Pfizer Inc, PharmaMar, Taiho Oncology Inc, Teva Oncology; Food and Beverage: Merck, Puma Biotechnology Inc; Royalties: Wolters Kluwer; Other: Boehringer Ingelheim Pharmaceuticals Inc, Merus BV. Prof Peters — Advisory Committee and Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biocartis, BioInvent International AB, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Daiichi Sankyo Inc, Debiopharm Group, F Hoffmann-La Roche Ltd, Foundation Medicine, Illumina Inc, Janssen Biotech Inc, Lilly, Merck Serono, Merck Sharp & Dohme Corp, Merrimack Pharmaceuticals Inc, Novartis, Pfizer Inc, PharmaMar, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Takeda Oncology; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, F Hoffmann-La Roche Ltd, Illumina Inc, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc; Data and Safety Monitoring Board/Committee: Academic trials. Dr Ramalingam — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck, Takeda Oncology; Contracted Research: Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Takeda Oncology, Tesaro, A GSK Company.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by education grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, Lilly and Merck.